Study guide
Section 4.12: Clinical Pharmacology: Oncology, Immunology, and Hematology
Saudi Pharmacist Licensure Examination SPLE - Pharmacist
Track your progress as you read
Finished sections get a check mark.
1 Introduction & Exam Overview
Section 0.1: About the Saudi Pharmacist Licensure Examination (SPLE) Section 0.2: How to Study and Prep for the SPLE
2 Chapter 1: Basic Biomedical Sciences
Section 1.1: Human Physiology & Pathophysiology Foundations Section 1.2: Medical Biochemistry & Enzymology Section 1.3: Medical Microbiology & Immunology Section 1.4: Molecular Genetics & Pharmacogenomics Foundations
3 Chapter 2: Pharmaceutical Sciences
Section 2.1: Medicinal Chemistry & Structure-Activity Relationships (SAR) Section 2.2: Drug ADME (Absorption, Distribution, Metabolism, Excretion) Section 2.3: General Pharmacology: Mechanisms of Drug Action Section 2.4: General Toxicology: Overdose, Antidotes & Adverse Drug Reactions (ADRs) Section 2.5: Pharmacognosy: Natural Products & Dietary Supplements Section 2.6: Basic Pharmaceutics & Dosage Form Design Section 2.7: Biopharmaceutics & Drug Delivery Systems Section 2.8: Applied Pharmacokinetics (PK): One-Compartment Models Section 2.9: Non-linear and Multi-compartment Pharmacokinetics Section 2.10: Sterile Compounding: Techniques & Quality Standards Section 2.11: Non-sterile Compounding & Product Formulation Section 2.12: Pharmaceutical Calculations: Dosing and Strengths Section 2.13: Pharmaceutical Calculations: Dilutions and Reconstitution Section 2.14: Pharmaceutical Calculations: Osmolarity, Milliequivalents, and Alligations
4 Chapter 3: Social, Behavioral, and Administrative Sciences
Section 3.1: Saudi Arabian Healthcare System & Public Health Policies Section 3.2: Pharmacoepidemiology & Post-Marketing Drug Surveillance Section 3.3: Pharmacovigilance & Drug Safety Monitoring in Saudi Arabia Section 3.4: Pharmacoeconomic Principles & Cost-Benefit Analysis Section 3.5: Pharmacy Management, Inventory, and Operations Section 3.6: Saudi Pharmacy Law & SFDA Regulations Section 3.7: Biostatistics, Clinical Trial Design & Literature Evaluation Section 3.8: Professional Ethics, Communication, and Dispensing Systems
5 Chapter 4: Clinical Sciences
Section 4.1: Drug Information Services & Evidence-Based Medicine Section 4.2: Clinical Pharmacokinetics & Therapeutic Drug Monitoring (TDM) Section 4.3: Clinical Pharmacogenomics & Personalized Therapeutics Section 4.4: Disease Prevention, Wellness, and Immunization Schedules Section 4.5: Patient Assessment & Physical Examination Interpretation Section 4.6: Clinical Pharmacology: Cardiovascular Disorders Section 4.7: Clinical Pharmacology: Renal & Urological Disorders Section 4.8: Clinical Pharmacology: Respiratory & Pulmonary Disorders Section 4.9: Clinical Pharmacology: Endocrine & Metabolic Disorders Section 4.10: Clinical Pharmacology: Infectious Diseases & Antimicrobial Stewardship Section 4.11: Clinical Pharmacology: Neurological & Psychiatric Disorders Section 4.12: Clinical Pharmacology: Oncology, Immunology, and Hematology Section 4.13: Clinical Pharmacology: Gastrointestinal & Hepatic Disorders Section 4.14: Therapeutic Decision-Making in Special Populations (Geriatrics, Pediatrics, Pregnancy, Lactation)
Section 4.12: Clinical Pharmacology: Oncology, Immunology, and Hematology
Key Takeaways Explain This Topic AI
Chemotherapeutic agents have distinct dose-limiting toxicities, such as doxorubicin-induced cardiotoxicity and vincristine-induced peripheral neuropathy, with vincristine being fatal if administered intrathecally.
Highly emetogenic chemotherapy regimens require a multi-drug prophylactic regimen consisting of an NK1 receptor antagonist, a 5-HT3 receptor antagonist, and dexamethasone.
Initiation of biological DMARDs like TNF-alpha inhibitors requires mandatory pre-screening for latent tuberculosis and hepatitis B virus to prevent reactivation.
Erythropoiesis-stimulating agents (ESAs) in chronic kidney disease are titrated to a target hemoglobin not exceeding 11 g/dL due to increased cardiovascular and thromboembolic risks.
Last updated: July 2026
Clinical Pharmacology: Oncology, Immunology, and Hematology
Oncology, immunology, and hematology cover therapeutic classes that require strict monitoring, adherence to supportive care guidelines, and understanding of patient safety precautions.
1. Oncology & Chemotherapy Regimens
Cancer chemotherapy involves cytotoxic agents with narrow therapeutic indices and high risks of severe toxicities. Pharmacists must be familiar with specific antidotes, lifetime cumulative dose limits, and preventative protocols:
Cytotoxic Class Toxicities & Clinical Pearls
Agent / Class Primary Toxicities Protective Agent / Antidote Clinical Pearls
Anthracyclines (e.g., Doxorubicin, Daunorubicin) Cardiotoxicity (acute arrhythmias, chronic cardiomyopathy/HF). Extravasation risk (vesicant). Dexrazoxane (cardioprotectant; used when cumulative dose exceeds thresholds; also used to treat extravasation). Lifetime cumulative dose limit of doxorubicin is 450–550 mg/m² . Red-orange discoloration of urine/sweat is normal.
Platinum Agents (e.g., Cisplatin, Carboplatin) Nephrotoxicity (cisplatin), ototoxicity, severe emetogenicity. Myelosuppression (dose-limiting for carboplatin). Amifostine (nephroprotectant). Aggressive IV hydration with normal saline is mandatory. Carboplatin is dosed using the Calvert Formula : Dose (mg) = Target AUC × ( GFR + 25 ) \text{Dose (mg)} = \text{Target AUC} \times (\text{GFR} + 25) Dose (mg) = Target AUC × ( GFR + 25 ) .
Vinca Alkaloids (e.g., Vincristine, Vinblastine) Peripheral neuropathy (dose-limiting for vincristine), severe constipation (autonomic neuropathy), extravasation (vesicant, treat with warm compresses and hyaluronidase). None. Vincristine is FATAL if administered intrathecally. It should only be given intravenously. Dispense in mini-bags to prevent accidental intrathecal administration.
Alkylating Agents (e.g., Cyclophosphamide, Ifosfamide) Hemorrhagic cystitis (caused by the metabolite acrolein binding to bladder wall), myelosuppression. Mesna (copiously binds acrolein in the bladder). Aggressive oral/IV hydration is required. Mesna is mandatory for all ifosfamide doses and high-dose cyclophosphamide.
Bleomycin Pulmonary toxicity (pulmonary fibrosis, pneumonitis). None. Lifetime cumulative dose limit is 400 units due to pulmonary toxicity risk. Baseline and periodic pulmonary function tests (DLCO) are required.
- 2. Managing Oncologic Toxicities
- Chemotherapy-Induced Nausea and Vomiting (CINV)
CINV prevention is based on the emetogenic potential of the chemotherapy regimen. For highly emetogenic regimens (e.g., Cisplatin, high-dose Cyclophosphamide), a 3- or 4-drug regimen is required starting on Day 1 of chemotherapy:
NK1 Receptor Antagonist: e.g., Aprepitant (oral) or Fosaprepitant (IV). Block substance P receptors.
5-HT3 Receptor Antagonist: e.g., Ondansetron, Palonosetron. Block serotonin receptors in the CTZ. Side effects: headache, constipation, QT prolongation (ondansetron).
Dexamethasone: Corticosteroid. Enhances antiemetic efficacy.
Optional: Olanzapine (often added to form a 4-drug regimen, highly effective for delayed nausea).
Febrile Neutropenia (FN)
Febrile neutropenia is an oncologic emergency defined as:
Fever: A single oral temperature measurement of > 38.3°C (101°F) or a sustained temperature of >= 38.0°C (100.4°F) for over one hour.
Neutropenia: An Absolute Neutrophil Count (ANC) < 500 cells/mm³ (or an ANC expected to decrease below 500 within 48 hours).
Management: Immediate administration of empiric IV broad-spectrum anti-pseudomonal beta-lactam antibiotics (e.g., Cefepime, Piperacillin-Tazobactam, Meropenem) is mandatory. Vancomycin is added if a catheter-related infection, pneumonia, or hemodynamic instability is present.
Prevention: Granulocyte Colony-Stimulating Factors (G-CSF) (e.g., Filgrastim, Pegfilgrastim) are indicated as primary prophylaxis in patients receiving chemotherapy regimens with a >= 20% risk of febrile neutropenia.
- 3. Immunology: Rheumatoid Arthritis & SLE
- Rheumatoid Arthritis (RA) DMARDs
Methotrexate (MTX): Gold standard first-line DMARD. Inhibits dihydrofolate reductase. Dosed ONCE WEEKLY (never daily for RA). Folic acid (1–5 mg daily or 5 mg weekly) must be co-prescribed to reduce GI and hematologic toxicities. Adverse effects: hepatotoxicity, myelosuppression, interstitial pneumonitis. Contraindicated in pregnancy.
Leflunomide: Inhibits pyrimidine synthesis. Teratogenic; requires a cholestyramine washout procedure if pregnancy is desired.
Hydroxychloroquine: Used for mild RA or in combination. Associated with retinal toxicity (requires baseline and annual ophthalmic examinations after 5 years of use).
Biological DMARDs (TNF-alpha inhibitors: Adalimumab, Infliximab, Etanercept): Effective but immunosuppressive. Mandatory screening for latent Tuberculosis (TB) and Hepatitis B Virus (HBV) is required before initiating any biologic DMARD due to the risk of reactivation. Live vaccines are contraindicated while receiving biologic therapy.
Systemic Lupus Erythematosus (SLE)
Hydroxychloroquine: Fundamental therapy for all patients with SLE to reduce flares and organ damage.
Corticosteroids: Used at the lowest effective dose for active flares.
Immunosuppressants: Mycophenolate mofetil (preferred for lupus nephritis) or Azathioprine. Azathioprine requires checking TPMT (thiopurine methyltransferase) enzyme activity before starting to avoid severe myelosuppression.
4. Hematology: Anemias
Iron Deficiency Anemia: Characterized by microcytic, hypochromic red blood cells ( M C V < 80 MCV < 80 MC V < 80 fL) and low ferritin. Treated with oral ferrous sulfate (325 mg daily/every other day). Counsel patients to take on an empty stomach with Vitamin C (enhances absorption) and avoid antacids, dairy, and tea. Side effects: constipation, dark stools. IV iron (e.g., Iron Dextran, Ferric Carboxymaltose) is used for oral intolerance or malabsorption. Iron dextran requires a test dose due to anaphylaxis risk.
Megaloblastic Anemias: Macrocytic ( M C V > 100 MCV > 100 MC V > 100 fL). Caused by Vitamin B12 or folate deficiency. Vitamin B12 deficiency (pernicious anemia due to lack of intrinsic factor) requires IM cyanocobalamin (1000 mcg daily for a week, then weekly, then monthly) or high-dose oral therapy.
Anemia of Chronic Kidney Disease (CKD): Caused by deficient erythropoietin production. Treated with Erythropoiesis-Stimulating Agents (ESAs) : Epoetin alfa, Darbepoetin alfa. Safety Warning: target hemoglobin must not exceed 11 g/dL due to increased risks of cardiovascular events, stroke, venous thromboembolism, and tumor progression in cancer patients.